

# The baseline characters of No.3 and No.4 clinical trials

	Simulated No.3 Clinical Trial (NCT03155997) n=197		Simulated No.4 Clinical Trial (NCT02513394) n=361	
	n	%	n	%
<b>Gender</b>				
Female	195	98.98%	358	99.17%
Male	2	1.02%	3	0.83%
<b>Age</b>				
20-30	1	0.51%	4	1.11%
31-40	20	10.15%	25	6.93%
41-50	38	19.29%	78	21.61%
51-60	58	29.44%	96	26.59%
61-70	49	24.87%	94	26.04%
71-80	22	11.17%	45	12.47%
81-90	9	4.57%	19	5.26%
<b>Ethnicity</b>				
American Indian or Alaska Native	0	0.00%	0	0.00%
Asian	14	7.11%	19	5.26%
Black or African American	26	13.20%	43	11.91%
White	135	68.53%	259	71.75%
Not reported	22	11.17%	40	11.08%
<b>AJCC pathologic stage</b>				
I	17	8.63%	0	0.00%
II	79	40.10%	257	71.19%
III	101	51.27%	104	28.81%
IV	0	0.00%	0	0.00%
X	0	0.00%	0	0.00%
Not reported	0	0.00%	0	0.00%
<b>Pathologic type at primary diagnosis</b>				
Infiltrating duct carcinoma, NOS	143	72.59%	252	69.81%
Lobular carcinoma, NOS	42	21.32%	89	24.65%
Infiltrating duct and lobular carcinoma	4	2.03%	7	1.94%
Infiltrating duct mixed with other types of carcinoma	4	2.03%	4	1.11%
Others	4	2.03%	6	1.66%
<b>Ki-67</b>				
<15%	112	56.85%	237	65.65%
>=15%	85	43.15%	124	34.35%

**Supplementary Table 2 | The baseline characteristics of the simulated No.3 and No.4 trials**